AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

GALECTIN THERAPEUTICS INC Director's Dealing 2017

Dec 18, 2017

33422_dirs_2017-12-18_3875060d-0128-4091-895f-4b01f0db1b79.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2017-12-14

Reporting Person: SHULMAN STEPHEN (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12000	Direct